

500 Chipeta Way Salt Lake City, UT 84108-1221 phone: 801-583-2787 | toll free: 800-242-2787 fax: 801-584-5249 | aruplab.com

GENOME SEQUENCING INTAKE FORM

Failure to provide required information for genome sequencing will RESULT in suboptimal clinical reports and delays in testing.

1.	Pro	band Patient Name:	Date of Birth:						
2.	Sus	Suspected Clinical Diagnosis:							
	Provide medical records detailing the patient's phenotype/relevant previous testing/family history or complete the Additional Clinical Information section found in this document.								
3.	Order Parental Control Samples Using Test Codes Below*. Submit comparator samples within 7 days of the proband's sample.								
	Controls REQUIRED for Rapid Whole Genome Sequencing (3005935) Rapid Whole Genome Sequencing, Familial Control (3005928)—If no ACMG report desired Rapid Whole Genome Sequencing, Familial Control with Report (3005933)—If ACMG report desired								
	Controls RECOMMENDED for Whole Genome Sequencing (3016493) Whole Genome Sequencing, Familial Control (3016497)—Opt in below if ACMG report desired								
	a. Maternal Last Name, First Name:								
		Date of birth:	Clinically affected? ☐ No ☐ Yes:						
	b. Paternal Last Name, First Name:								
	b.	Paternal Last Name	First Name:						

*Parental samples must arrive within 7 days of proband's order and are critical for optimal analysis. Nonparental controls are not acceptable. Due to the required clinical workflow, submitted nonparental controls may be sequenced, and if so, additional charges will apply.

4. Ordering Provider Attestation of Informed Consent (signature required below)

Test Purpose and Description

The purpose of whole genome sequencing is to identify the gene variant(s) causing a suspected genetic condition. Testing requires drawing 2 mL of blood from which the DNA is extracted. DNA codes for genes. Most of the patient's genes will be sequenced. Thousands of DNA variants will be detected by sequencing. DNA variants may be disease causing or harmless; however, the effect of many DNA variants is currently unknown.

Ordering Considerations

Participation in whole genome sequencing is voluntary. Genetic counseling is recommended before and following this complex test.

The chance a cause for the patient's medical issue(s) can be determined using this test varies and is influenced by the specific clinical features present. Diagnostic rates are highest when biological parents' samples are included as comparators for whole genome sequencing. Parental

sequence data is used to identify de novo (new) changes in the patient's DNA, not found in either parent, that could explain the patient's disorder.

It is important that the familial biological relationships are correctly stated because undisclosed adoption or uncertain paternity will cause confusion and decrease the chance of identifying the causative disease variant.

Whole genome sequencing may identify genetic findings unrelated to the original reason for testing such as:

- Predict another family member has, is at risk for, or is a carrier of an unsuspected genetic condition.
- Reveal nonpaternity (the person stated to be the biological father is not, in fact, the biological father).
- Indicate the biological parents of the patient are close blood relatives (consanguineous).

GENOME SEQUENCING INTAKE FORM

Reporting of Results

Results are generally available in 1 week for rapid whole genome sequencing and within 3 weeks for nonrapid whole genome sequencing. Variants related to the patient's medical issues are reported.

All variants identified in the patient that are related to the patient's primary disorder will be tested in familial controls. The status of all primary variants tested in controls will be indicated on the proband's report.

Variants unrelated to the patient's medical condition are not usually reported except for disease-causing secondary findings (see the Secondary Findings section below).

Because genetic knowledge is advancing at a rapid pace, reanalysis of whole genome sequencing data should be considered 12–18 months after testing is complete if a cause for the patient's condition was not determined. ARUP will perform reanalysis (ARUP test code 3005939) of whole genome data for a fee. If the report is amended, the ordering provider will be contacted with an updated report.

Limitations

Although genetic test results are usually accurate, several sources of error are possible, including clinical misdiagnosis of a condition, sample mislabeling or contamination, transfusion, bone marrow transplantation, maternal cell contamination of cord blood samples, or inaccurate information regarding biological relationships. If biological relationships are inaccurately reported, it could lead to an incorrect diagnosis or inconclusive result. ARUP will contact the referring provider if nonpaternity and/or consanguinity is detected but that information will not be included in the patient's report.

Often, whole genome sequencing is not able to identify the cause of a patient's medical issues. This does not exclude the possibility that the patient has a genetic condition. Some disease-causing variants are in genes with unknown function while others may not be identifiable using this test. Examples of variants not detectable with this test include large gene deletion/duplications, chromosome rearrangements, inversions, methylation abnormalities, and those causing repeat disorders. This test does not include sequencing of the mitochondrial genome.

Secondary Findings

The American College of Medical Genetics and Genomics (ACMG) recommends reporting disease-causing variants in specific genes that increase the risk for developing cancer, cardiovascular issues, metabolic disorders, problems with anesthesia, retinopathy, and other conditions where monitoring or early treatment may be available. Please refer to the latest version of the ACMG recommendations for reporting secondary findings in clinical whole genome sequencing for a list of genes and associated disorders

tested. Additional medically actionable variants in non-ACMG genes may be reported at ARUP's discretion.

If a patient has symptoms of a condition related to an ACMG recommended gene, separate testing should be ordered, as coverage of ACMG genes may be incomplete. Only variants in ACMG genes identified by routine whole genome sequencing are reported. Single disease-causing variants in recessive ACMG genes are not reported.

To receive secondary findings about the patient, the patient (or their legal guardian) would need to choose to receive this information by selecting the "opt-in" option on this form. Familial controls who desire a report of their own secondary findings can also opt-in to receive this information for a separate fee. Secondary findings will be reported for familial controls who elect to receive this information regardless of whether the finding was also identified in the patient. Parental inheritance of secondary findings identified in the patient will only be included in the patient's report if the positive parent also opts to receive secondary findings.

If a disease-causing genetic variant is identified, insurance rates, the ability to obtain disability and life insurance, and employability could be affected. The Genetic Information Nondiscrimination Act of 2008 extends some protections against genetic discrimination (genome.gov/10002328). All test results are released to the ordering healthcare provider and those parties entitled to them by federal, state, and local laws.

Access to Sequence Data/Data Sharing/Sample Storage

ARUP Laboratories will have access to the patient's sequence data from whole genome sequencing. Your healthcare provider and the hospital that submitted the test to ARUP can also request a copy of the sequence data.

Because ARUP is not a storage facility, most samples are discarded after testing is completed. Some samples may be stored indefinitely for test validation or education purposes after personal identifiers are removed. You may request disposal of your sample by calling ARUP Laboratories at 800-242-2787 ext. 3301.

In cooperation with the National Institutes of Health's effort to improve understanding of specific genetic variants, ARUP submits HIPAA-compliant, deidentified (cannot be traced back to the patient) genetic test results and health information to public databases. The confidentiality of each sample is maintained. If you prefer that your test result not be shared, call ARUP at 800-242-2787 ext. 3301. Your deidentified information will not be disclosed to public databases after your request is received, but a separate request is required for each genetic test. Additionally, patients have the opportunity to participate in patient registries and research. To learn more, visit aruplab.com/genetics.

GENOME SEQUENCING INTAKE FORM

Ordering Healthcare Provider, Genetic Counselor: 1) I attest that I am the ordering health care provider or certified genetic counselor; 2) I have explained the purpose/benefits and limitations of the test to the patient or their legal guardian and all parental controls; 3) The patient/legal guardian and parental controls were offered copies of this consent document; 4) I have answered all their questions regarding the purpose of the test, the reporting of primary and secondary findings, the use and retention of samples, and data-sharing.

Ordering Provider/Genetic Counselor Printe	ed Name Signa	ture	Date						
Secondary findings identified WILL NOT be examined and reported for the patient or controls UNLESS the corresponding box is checked. A fee applies for generating a clinical report with secondary findings for control individuals.									
$\hfill\Box$ Opt-in to report secondary findings for the	ne PATIENT.								
☐ Opt-in to report secondary findings for the MATERNAL CONTROL.									
□ Opt-in to report secondary findings for the PATERNAL CONTROL.									
For questions, contact an ARUP genetic counselor at 800-242-2787 ext. 2141.									
Additional Clinical Information: Please provide medical records detailing the patient's phenotype/relevant previous testing/family history or complete the Additional Clinical Information section below. The ability to identify causative variant(s) for the patient's presentation is influenced by the quality of the clinical information provided.									
Ordering Provider:		Provider's Phone:							
Practice Specialty:		Provider's Fax:							
Genetic Counselor:		Counselor's Phone:							
Ethnicity/Ancestry: \square African American/B	lack □ Asian	☐ Hispanic ☐ Wh	ite 🗆 Other:						
Genes of Interest:									
Family History:									
PRE/PERINATAL □ 0000776 Congenital diaphragmatic hernia □ 0001627 Congenital heart defect □ 0000476 Cystic hygroma □ 0002084 Encephalocele □ 0010945 Fetal pyelectasis □ 0007430 Generalized edema □ 0001789 Hydrops fetalis □ 0010880 Increased nuchal translucency □ 0001511 Intrauterine growth restriction □ 0002475 Myelomeningocele/spina bifida □ 0001562 Oligohydramnios □ 0001561 Polyhydramnios □ 0001622 Prematurity−GA at birth	□ 0002134 Abnorn	nality of neuronal n/hypoplasia of the trophy al dysmyelination al hypomyelination al white matter al dysplasia topia osencephaly ephalus	NEUROLOGICAL O100022 Abnormality of movement O001284 Areflexia O001251 Ataxia O002015 Dysphagia O100660 Dyskinesia O200134 Epileptic encephalopathy O001298 Encephalopathy O001347 Hyperreflexia O004305 Involuntary movements O002121 Absence O002373 Febrile O007359 Focal O002123 Generalized myoclonic O11169 Generalized clonic						
□ 0003026 Short long bones □ 0001518 Small for gestational age □	☐ 0001339 Lissend☐ 0002126 Polymi☐ 0002119 Ventric	crogyria	☐ 0002069 Tonic-clonic						

ARUP-FORM-0014, Rev 2 | September 2024 | Page 3 of 5

GENOME SEQUENCING INTAKE FORM

METABOLIC	CRANIOFACIAL	☐ 0002021 Pyloric stenosis
□ 0040081 Abnormal CK	□ 0000271 Abnormal facies	☐ 0001744 Splenomegaly
□ 0001941 Acidosis	□ 0000306 Abnormality of the nose	
	•	☐ 0002013 Vomiting
☐ 0003234 Decreased plasma carnitine	□ 0000290 Abnormality of the forehead	
□ 0003348 Hyperalaninemia	☐ 0000175 Cleft palate	GENITOURINARY
☐ 0001943 Hypoglycemia	☐ 041 0030 Cleft lip	☐ 0000812 Abnormal internal genitalia
☐ 0001987 Hyperammonemia	☐ 0001363 Craniosynostosis	☐ 0000062 Ambiguous genitalia
☐ 0002490 Increased CSF lactate	☐ 0000286 Epicanthus	☐ 0000028 Cryptorchidism
☐ 0003542 Increased serum pyruvate	□ 0000316 Hypertelorism	□ 0000085 Horseshoe kidney
☐ 0001946 Ketosis	□ 0000601 Hypotelorism	□ 0000126 Hydronephrosis
☐ 0003128 Lactic acidosis	☐ 0000256 Macrocephaly	☐ 0000047 Hypospadias
☐ 0001942 Metabolic acidosis	☐ 0000252 Microcephaly	☐ 0008738 Partially duplicated kidney
☐ 0001992 Organic aciduria		
☐ Abnormal newborn screen	EYE AND VISION	☐ 0000113 Polycystic kidney dysplasia
		☐ 0000107 Renal cyst
	□ 0000526 Aniridia	☐ 0000104 Renal agenesis
	□ 0000528 Anophthalmia	☐ 0000089 Renal hypoplasia
DEVELOPMENTAL/BEHAVIORAL	□ 0000618 Blindness	☐ 0000069 Ureter abnormality
□ 0007018 Attention deficit hyperactivity	☐ 0000589 Coloboma	☐ 0000795 Urethra abnormality
disorder	☐ 0000519 Congenital cataract	
☐ 0000729 Autistic spectrum disorder	☐ 0000568 Microphthalmia	SKIN AND HAIR
□ 0000750 Delayed speech and language	☐ 0000639 Nystagmus	□ 0008066 Blistering of skin
development	☐ 0000648 Optic atrophy	
\square 0002376 Developmental regression	☐ 0000508 Ptosis	□ 0000957 Café-au-lait spot
□ 0001263 Global developmental delay	☐ 0009919 Retinoblastoma	☐ 0005306 Capillary hemangioma
☐ 0001249 Intellectual disability	☐ 0000486 Strabismus	☐ 0001595 Hair abnormality
☐ 0002187 Profound	□ 0000505 Visual impairment	\square 0000974 Hyperextensible skin
☐ 0010864 Severe		\square 0000953 Hyperpigmentation of skin
☐ 0002342 Moderate		☐ 0000998 Hypertrichosis
□ 0001256 Mild	EAR AND HEARING	□ 0001010 Hypopigmentation of skin
☐ 0001270 Motor delay	☐ 0000377 Abnormal external ear	☐ 0008066 Ichthyosis
,	☐ 0000405 Conductive hearing	☐ 0001597 Nail abnormality
·	impairment	☐ 0001581 Recurrent skin infections
MUSCULOSKELETAL	☐ 0000410 Mixed hearing impairment	
☐ 0002804 Arthrogryposis multiplex	☐ 0000407 Sensorineural hearing	
congenita	impairment	HEMATOLOGY AND IMMUNOLOGY
☐ 0003199 Decreased muscle mass		☐ 0001928 Abnormality of coagulation
☐ 0001371 Flexion contracture	CARDIAC	☐ 0004432 Agammaglobulinemia
☐ 0001528 Hemihypertrophy	□ 0001713 Abnormal cardiac ventricle	☐ 0001903 Anemia
☐ 0001252 Hypotonia		☐ 0031020 Bone marrow hypercellularity
☐ 0001276 Hypertonia	□ 0002616 Aortic root dilatation	□ 0001878 Hemolytic anemia
☐ 0001382 Joint hypermobility	□ 0011675 Arrhythmia	☐ 0002721 Immunodeficiency
☐ 0002808 Kyphosis	☐ 0001631 Atrial septal defect	☐ 0001888 Lymphopenia
□ 0040064 Limb abnormality	☐ 0001647 Bicuspid aortic valve	☐ 0001875 Neutropenia
☐ 0001324 Muscle weakness	☐ 0001638 Cardiomyopathy	☐ 0001876 Pancytopenia
☐ 0003198 Myopathy	☐ 0001680 Coarctation of aorta	☐ 0002719 Recurrent infections
□ 0010442 Polydactyly	□ 0001642 Pulmonary stenosis	☐ 0004430 Severe combined
□ 0002757 Recurrent fractures	☐ 0001636 Tetralogy of Fallot	immunodeficiency
□ 0002757 Recurrent nactures □ 0002650 Scoliosis	☐ 0001629 Ventricular septal defect	☐ 0001873 Thrombocytopenia
□ 0004322 Short stature		
	O A OTTO INITECTINAL	
☐ 0002652 Skeletal dysplasia	GASTROINTESTINAL	
□ 0001257 Spasticity	□ 0002251 Aganglionic megacolon	
□ 0001159 Syndactyly	☐ 0002910 Elevated hepatic transaminase	
☐ 0001762 Talipes equinovarus	☐ 0001508 Failure to thrive	
☐ 0000098 Tall stature	☐ 0001543 Gastroschisis	
☐ 0000925 Vertebral column abnormality	□ 0001399 Hepatic failure	
	☐ 0002240 Hepatomegaly	

ARUP-FORM-0014, Rev 2 | September 2024 | Page 4 of 5

GENOME SEQUENCING INTAKE FORM ENDOCRINE OTHER ☐ 0000829 Hypoparathyroidism ☐ 0000834 Abnormality of adrenal glands □ 0008226 Androgen insufficiency CANCER ☐ 0008258 Congenital adrenal □ Type of cancer ____ hyperplasia ☐ Age of diagnosis ___ ☐ 0000819 Diabetes mellitus ☐ Family history of cancer and ☐ 0000873 Diabetes insipidus affected relatives ☐ 0001738 Exocrine pancreatic insufficiency □ 0000821 Hypothyroidism PREVIOUS TESTING (provide copy of abnormal results) Echocardiogram: Not performed □ Normal □ Abnormal EEG: \square Not performed □ Normal □ Abnormal_ EMG/NCV: ☐ Not performed □ Normal □ Abnormal □ Normal □ Abnormal Gene testing: _ Gene testing: _ □ Normal □ Abnormal Karyotype: ☐ Not performed □ Normal □ Abnormal Prenatal genomic microarray: ☐ Not performed □ Normal □ Abnormal Postnatal genomic microarray: □ Not performed □ Normal ☐ Abnormal MRI (brain): □ Not performed □ Normal □ Abnormal MRI (other): □ Not performed □ Normal □ Abnormal CT (brain): ☐ Not performed □ Normal ☐ Abnormal CT (other): ☐ Not performed □ Normal □ Abnormal Muscle biopsy: ☐ Not performed □ Normal □ Abnormal Ultrasound ☐ Not performed □ Normal □ Abnormal _ X-ray: ☐ Not performed □ Normal □ Abnormal _ Other test: □ Normal □ Abnormal Other test:_ □ Normal □ Abnormal _ Other test: □ Normal □ Abnormal